Abstract
Chronic lymphocytic leukemia (CLL) is a clinically heterogeneous disease characterized by the accumulation/expansion of a clonal population of small mature B lymphocytes in blood, bone marrow, and lymphoid organs. Although initial genetic events are considered primarily responsible for the first step(s) of neoplastic transformation, the development and progression of the CLL clone are thought to be affected by various micro-environmental signals that regulate proliferation and survival of malignant B cells. In the present review, we focus on specific interactions of CLL cells with the microenvironmental component, as they occur through the usage by CLL cells of specific molecular structures whose expression has been associated with prognosis, including: i) interactions of CLL cells via the surface BCR and dependent on specific molecular features of the BCR itself and/or the presence of the BCR-associated molecule ZAP- 70; ii) non-BCR-dependent proliferative and/or pro-survival interactions of CLL cells by CD49d and CD38. An overview of the putative drugs that could be employed to target specific molecules involved in CLL cells/tumor microenvironment interactions is also proposed in the closing chapter of the review.
Keywords: Chronic lymphocytic leukemia, microenvironment, therapy, B lymphocytes, neoplastic transformation, BCR, CD49d, CD38, putative drugs, lymphoid organs
Current Pharmaceutical Design
Title:Microenvironmental Interactions in Chronic Lymphocytic Leukemia: Hints for Pathogenesis and Identification of Targets for Rational Therapy
Volume: 18 Issue: 23
Author(s): Michele Dal Bo, Riccardo Bomben, Antonella Zucchetto, Giovanni Del Poeta, Gianluca Gaidano, Silvia Deaglio, Dimitar G. Efremov and Valter Gattei
Affiliation:
Keywords: Chronic lymphocytic leukemia, microenvironment, therapy, B lymphocytes, neoplastic transformation, BCR, CD49d, CD38, putative drugs, lymphoid organs
Abstract: Chronic lymphocytic leukemia (CLL) is a clinically heterogeneous disease characterized by the accumulation/expansion of a clonal population of small mature B lymphocytes in blood, bone marrow, and lymphoid organs. Although initial genetic events are considered primarily responsible for the first step(s) of neoplastic transformation, the development and progression of the CLL clone are thought to be affected by various micro-environmental signals that regulate proliferation and survival of malignant B cells. In the present review, we focus on specific interactions of CLL cells with the microenvironmental component, as they occur through the usage by CLL cells of specific molecular structures whose expression has been associated with prognosis, including: i) interactions of CLL cells via the surface BCR and dependent on specific molecular features of the BCR itself and/or the presence of the BCR-associated molecule ZAP- 70; ii) non-BCR-dependent proliferative and/or pro-survival interactions of CLL cells by CD49d and CD38. An overview of the putative drugs that could be employed to target specific molecules involved in CLL cells/tumor microenvironment interactions is also proposed in the closing chapter of the review.
Export Options
About this article
Cite this article as:
Dal Bo Michele, Bomben Riccardo, Zucchetto Antonella, Del Poeta Giovanni, Gaidano Gianluca, Deaglio Silvia, G. Efremov Dimitar and Gattei Valter, Microenvironmental Interactions in Chronic Lymphocytic Leukemia: Hints for Pathogenesis and Identification of Targets for Rational Therapy, Current Pharmaceutical Design 2012; 18 (23) . https://dx.doi.org/10.2174/138161212801227078
DOI https://dx.doi.org/10.2174/138161212801227078 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Extracellular Production of the Oncolytic Enzyme, L-Asparaginase, by Newly Isolated Streptomyces sp. Strain NEAE-95 as Potential Microbial Cell Factories: Optimization of Culture Conditions Using Response Surface Methodology
Current Pharmaceutical Biotechnology The Mechanistic Links Between Proteasome Activity, Aging and Agerelated Diseases
Current Genomics Lipid-Based Drug Delivery Systems for Cancer Treatment
Current Drug Targets Emerging Molecular Functions of MicroRNA-9: Cancer Pathology and Therapeutic Implications
Anti-Cancer Agents in Medicinal Chemistry Posterior Reversible Encephalopathy Syndrome in Leukemic Children: A Sensitive Issue
Current Drug Safety A New Synthetic Spiroketal: Studies on Antitumor Activity on Murine Melanoma Model In Vivo and Mechanism of Action In Vitro
Anti-Cancer Agents in Medicinal Chemistry Molecular Targeting of Protein Kinases to Optimize Selectivity and Resistance Profiles of Kinase Inhibitors
Current Topics in Medicinal Chemistry The Anticancer Properties of Dietary Polyphenols and its Relation with Apoptosis
Current Pharmaceutical Design The PI3K Pathway at the Crossroads of Cancer and the Immune System: Strategies for Next Generation Immunotherapy Combinations
Current Cancer Drug Targets On the Generation of Novel Anticancer Drugs by Recombinant DNA Technology: The Use of Combinatorial Biosynthesis to Produce Novel Drugs
Combinatorial Chemistry & High Throughput Screening Iron Chelating Strategies in Systemic Metal Overload, Neurodegeneration and Cancer
Current Medicinal Chemistry Novel Concepts in the Development of Platinum Antitumour Drugs: An Update
Medicinal Chemistry Reviews - Online (Discontinued) TNF-Related Apoptosis-Inducing Ligand (TRAIL): A Potential Candidate for Combined Treatment of Hematological Malignancies
Current Pharmaceutical Design Structure and Function of the Human Breast Cancer Resistance Protein (BCRP/ABCG2)
Current Drug Metabolism Recent Research Trends on Bismuth Compounds in Cancer Chemoand Radiotherapy
Current Medicinal Chemistry Recent Advances in Regulatory T Cell Therapy of Autoimmunity, Graft Rejection and Cancer
Recent Patents on Inflammation & Allergy Drug Discovery Unravelling the Role of Infectious Agents in the Pathogenesis of Human Autoimmunity: The Hypothesis of the Retroviral Involvement Revisited
Current Molecular Medicine Small Molecule Inhibitors of Protein Kinases in Cancer- How to Overcome Resistance
Mini-Reviews in Medicinal Chemistry Progress Toward Vector Design for Hematopoietic Stem Cell Gene Therapy
Current Gene Therapy Ring Opening of Tetrazole via Unusual Vilsmeir-Haack Reaction Forming Novel Triazenes
Letters in Organic Chemistry